BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24

• Press Releases

  IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

  September 24, 2026

   · 

  12 min read
• Press Releases

  Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic health

  September 24, 2026

   · 

  3 min read
• Press Releases

  SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

  September 24, 2026

   · 

  4 min read
• Press Releases

  Claris Bio Establishes Corporate Headquarters in San Francisco

  September 24, 2026

   · 

  2 min read
• Press Releases

  Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

  September 24, 2026

   · 

  10 min read
• Press Releases

  Biolinq Shine™ Receives FDA 510(k) Clearance for Over-the-Counter Use

  September 24, 2026

   · 

  2 min read
• Press Releases

  Precision Neuroscience Closes Oversubscribed $250M Series D Led by Pershing Square Inc., the Ackman Oxman Institute, and a Leading Life Sciences Investment Fund

  September 24, 2026

   · 

  3 min read
• Press Releases

  Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma

  September 24, 2026

   · 

  3 min read
• Press Releases

  Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

  September 24, 2026

   · 

  7 min read
• Press Releases

  Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

  September 24, 2026

   · 

  5 min read